Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HIV-1 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : DAIDS
Deal Size : $364.5 million
Deal Type : Partnership
ABL Awarded NIH Contract for Continued Support of HIV Vaccine Development
Details : ABL will provide DAIDS with preclinical and translational development of promising vaccines and related products for HIV and other candidate agents.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
October 20, 2022
Lead Product(s) : HIV-1 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : DAIDS
Deal Size : $364.5 million
Deal Type : Partnership
Reset All
